Gregory P Hess1, Pradeep Natarajan1, Kamil F Faridi1, Anna Fievitz1, Linda Valsdottir1, Robert W Yeh2. 1. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (G.P.H.). Scientific Studies & Projects, Symphony Health, Conshohocken, PA (G.P.H., A.F.). Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, Boston (P.N.). Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA (P.N.). Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (K.F.F., L.V., R.W.Y.). 2. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (G.P.H.). Scientific Studies & Projects, Symphony Health, Conshohocken, PA (G.P.H., A.F.). Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, Boston (P.N.). Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA (P.N.). Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (K.F.F., L.V., R.W.Y.). ryeh@bidmc.harvard.edu.
Abstract
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a novel class of medications for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional lipid lowering beyond dietary measures and statin use. Because of the drugs' high cost, rates of prescription approval by payers may be low. We aimed to identify payer approval and rejection rates for PCSK9i prescriptions and the potential factors influencing these rates. METHODS: This is a retrospective, descriptive cohort study using nationwide pharmacy claims linked to electronic medical records from a nationwide data warehouse. The data set includes >220 million patients from all 50 states and all payer types with 5140 distinct health plans. PCSK9i prescriptions were submitted for 51 466 patients in the pharmacy data set. The main outcome was approval or rejection of PCSK9i prescription claims. Factors associated with approval and rejection of these medications in the United States were assessed. RESULTS: Among patients who were prescribed a PCSK9i, 47.0% were approved for coverage by the payer. Variables that were associated with PCSK9i approval included age >65 years (P<0.01), history of atherosclerotic cardiovascular disease (P<0.01), prescription by a cardiologist or nonprimary care provider (P<0.01), statin intolerance (P=0.03), longer statin duration (P=0.01), and noncommercial payers (P<0.01). Higher low-density lipoprotein cholesterol levels were not associated with higher approval rates. Commercial third-party payers had the lowest approval rates (24.4%) and Medicare had the highest (60.9%). CONCLUSIONS: Rates of approval for PCSK9i therapy are low, even for patients who appear to meet labeled indications. Although a combination of clinical characteristics increases the likelihood of approval, payer type is the most significant factor.
BACKGROUND:Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a novel class of medications for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional lipid lowering beyond dietary measures and statin use. Because of the drugs' high cost, rates of prescription approval by payers may be low. We aimed to identify payer approval and rejection rates for PCSK9i prescriptions and the potential factors influencing these rates. METHODS: This is a retrospective, descriptive cohort study using nationwide pharmacy claims linked to electronic medical records from a nationwide data warehouse. The data set includes >220 million patients from all 50 states and all payer types with 5140 distinct health plans. PCSK9i prescriptions were submitted for 51 466 patients in the pharmacy data set. The main outcome was approval or rejection of PCSK9i prescription claims. Factors associated with approval and rejection of these medications in the United States were assessed. RESULTS: Among patients who were prescribed a PCSK9i, 47.0% were approved for coverage by the payer. Variables that were associated with PCSK9i approval included age >65 years (P<0.01), history of atherosclerotic cardiovascular disease (P<0.01), prescription by a cardiologist or nonprimary care provider (P<0.01), statin intolerance (P=0.03), longer statin duration (P=0.01), and noncommercial payers (P<0.01). Higher low-density lipoprotein cholesterol levels were not associated with higher approval rates. Commercial third-party payers had the lowest approval rates (24.4%) and Medicare had the highest (60.9%). CONCLUSIONS: Rates of approval for PCSK9i therapy are low, even for patients who appear to meet labeled indications. Although a combination of clinical characteristics increases the likelihood of approval, payer type is the most significant factor.
Authors: Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo Journal: JAMA Date: 2016-08-16 Impact factor: 56.272
Authors: Norah A Terrault; Stefan Zeuzem; Adrian M Di Bisceglie; Joseph K Lim; Paul J Pockros; Lynn M Frazier; Alexander Kuo; Anna S Lok; Mitchell L Shiffman; Ziv Ben Ari; Lucy Akushevich; Monika Vainorius; Mark S Sulkowski; Michael W Fried; David R Nelson Journal: Gastroenterology Date: 2016-08-24 Impact factor: 22.682
Authors: Da-Wei Zhang; Thomas A Lagace; Rita Garuti; Zhenze Zhao; Meghan McDonald; Jay D Horton; Jonathan C Cohen; Helen H Hobbs Journal: J Biol Chem Date: 2007-04-23 Impact factor: 5.157
Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins Journal: Lancet Date: 2010-11-08 Impact factor: 79.321
Authors: Tina M Kaufman; Bruce A Warden; Jessica Minnier; Joshua R Miles; P Barton Duell; Jonathan Q Purnell; Cezary Wojcik; Sergio Fazio; Michael D Shapiro Journal: Circ Res Date: 2019-01-04 Impact factor: 17.367
Authors: Hans-Georg Eichler; Mark Trusheim; Brigitte Schwarzer-Daum; Kay Larholt; Markus Zeitlinger; Martin Brunninger; Michael Sherman; David Strutton; Gigi Hirsch Journal: Clin Pharmacol Ther Date: 2021-11-17 Impact factor: 6.903
Authors: Alanna M Chamberlain; Yan Gong; Kathryn McAuliffe Shaw; Jiang Bian; Wen-Liang Song; MacRae F Linton; Vivian Fonseca; Eboni Price-Haywood; Emily Guhl; Jordan B King; Rashmee U Shah; Jon Puro; Elizabeth Shenkman; Pamala A Pawloski; Karen L Margolis; Adrian F Hernandez; Rhonda M Cooper-DeHoff Journal: J Am Heart Assoc Date: 2019-05-07 Impact factor: 5.501
Authors: Jakob Solgaard Jensen; Peter Ejvin Weeke; Lia Evi Bang; Dan Eik Høfsten; Maria Sejersten Ripa; Anne-Marie Schjerning; Juliane Elizabeth Theilade; Lars Valeur Køber; Gunnar Hilmar Gislason; Jannik Pallisgaard Journal: BMJ Open Date: 2019-04-01 Impact factor: 2.692
Authors: Monica M Parks; Eric A Secemsky; Robert W Yeh; Changyu Shen; Eunhee Choi; Dhruv S Kazi; Priscilla Y Hsue Journal: Eur Heart J Qual Care Clin Outcomes Date: 2021-05-03